Timothy Yap, MBBS, PhD, FRCP
Advertisement
Articles by Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.
Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.
Timothy Yap, MBBS, PhD, FRCP, discusses data for saruparib in harboring BRCA1/2, PALB2, or RAD51C/D mutations.
Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.
Advertisement
Latest Updated Articles
Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid TumorsPublished: October 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5